1. A nuclear beacon of hope: an advanced, metastatic glucagonoma treated with [177Lu]Lu-DOTA-TATE.
- Author
-
Kłosińska M, Kołodziej J, Mróz A, Mądra W, and Kamiński G
- Subjects
- Humans, Neoplasm Metastasis, Male, Middle Aged, Glucagonoma diagnostic imaging, Organometallic Compounds therapeutic use, Octreotide analogs & derivatives, Octreotide therapeutic use, Pancreatic Neoplasms diagnostic imaging, Pancreatic Neoplasms radiotherapy, Pancreatic Neoplasms pathology
- Abstract
Glucagonoma is a rare pancreatic neuroendocrine tumor (panNET) that can be characterized by increased secretion of glucagon and distinguishing symptoms - glucagonoma syndrome with a typical dermatosis, necrolytic migratory erythema, being its most common manifestation. While surgery and somatostatin analogs remain first-line therapeutic options in panNETs, radioligand therapy with [177Lu]Lu-DOTA-TATE is a recommended second-line palliative treatment in advanced, metastatic cases. However, its prospects and efficacy are still not vastly researched in less frequent neuroendocrine neoplasms. Here, we present an extraordinary case of a metastatic glucagonoma treated with [177Lu]Lu-DOTA-TATE used as a second-line treatment in progressive disease.
- Published
- 2024
- Full Text
- View/download PDF